[Malignant lymphoma and adult T-cell leukemia-lymphoma]

Rinsho Ketsueki. 2014 Feb;55(2):191-200.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cisplatin / administration & dosage
  • Cyclophosphamide / administration & dosage
  • Cytarabine / administration & dosage
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Dexamethasone / administration & dosage
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Genetic Markers
  • Genetic Testing
  • Hodgkin Disease / diagnosis
  • Hodgkin Disease / drug therapy*
  • Hodgkin Disease / genetics
  • Humans
  • Leukemia-Lymphoma, Adult T-Cell / diagnosis
  • Leukemia-Lymphoma, Adult T-Cell / drug therapy*
  • Leukemia-Lymphoma, Adult T-Cell / genetics
  • Lymphoma, Non-Hodgkin / diagnosis
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Lymphoma, Non-Hodgkin / genetics
  • Methylprednisolone / administration & dosage
  • Positron-Emission Tomography
  • Prednisone / administration & dosage
  • Vincristine / administration & dosage

Substances

  • Genetic Markers
  • Cytarabine
  • Deoxycytidine
  • Vincristine
  • Etoposide
  • Dexamethasone
  • Doxorubicin
  • Cyclophosphamide
  • Cisplatin
  • Prednisone
  • Methylprednisolone

Supplementary concepts

  • CHOP protocol
  • DHAP protocol
  • EPOCH protocol
  • ESAP protocol
  • GDP protocol